124 related articles for article (PubMed ID: 7671171)
1. Effects on bone mineral density of 12-month goserelin treatment in over 40-year-old women with uterine myomas.
Bianchi S; Fedele L; Vignali M; Galbiati E; Cherubini R; Ortolani S
Calcif Tissue Int; 1995 Jul; 57(1):78-80. PubMed ID: 7671171
[TBL] [Abstract][Full Text] [Related]
2. [Effect of GnRH analogues on bone density in the vertebral column and the femur].
Perrone G; Galoppi P; Critelli C; Bazzoffi R; Capri O; Barillaro F; Zichella L
Minerva Ginecol; 1995 Oct; 47(10):461-5. PubMed ID: 8559437
[TBL] [Abstract][Full Text] [Related]
3. Gonadotropin releasing hormone agonist treatment before hysterectomy for menorrhagia and uterine leiomyomas.
Vercellini P; Bocciolone L; Colombo A; Vendola N; Meschia M; Bolis G
Acta Obstet Gynecol Scand; 1993 Jul; 72(5):369-73. PubMed ID: 8392268
[TBL] [Abstract][Full Text] [Related]
4. Goserelin acetate to avoid hysterectomy in pre-menopausal women with fibroids requiring surgery.
Parazzini F; Bortolotti A; Chiantera V; Scollo P; Del Monaco D; Bianchi M; Bennici S
Eur J Obstet Gynecol Reprod Biol; 1999 Nov; 87(1):31-3. PubMed ID: 10579613
[TBL] [Abstract][Full Text] [Related]
5. Goserelin acetate 10.8 mg plus iron versus iron monotherapy prior to surgery in premenopausal women with iron-deficiency anemia due to uterine leiomyomas: results from a Phase III, randomized, multicenter, double-blind, controlled trial.
Muneyyirci-Delale O; Richard-Davis G; Morris T; Armstrong J
Clin Ther; 2007 Aug; 29(8):1682-91. PubMed ID: 17919549
[TBL] [Abstract][Full Text] [Related]
6. Bone metabolism in postmenopausal women who were treated with a gonadotropin-releasing hormone agonist and tibolone.
Palomba S; Morelli M; Di Carlo C; Noia R; Pellicano M; Zullo F
Fertil Steril; 2002 Jul; 78(1):63-8. PubMed ID: 12095492
[TBL] [Abstract][Full Text] [Related]
7. Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudy.
Gnant M; Mlineritsch B; Luschin-Ebengreuth G; Kainberger F; Kässmann H; Piswanger-Sölkner JC; Seifert M; Ploner F; Menzel C; Dubsky P; Fitzal F; Bjelic-Radisic V; Steger G; Greil R; Marth C; Kubista E; Samonigg H; Wohlmuth P; Mittlböck M; Jakesz R;
Lancet Oncol; 2008 Sep; 9(9):840-9. PubMed ID: 18718815
[TBL] [Abstract][Full Text] [Related]
8. Role of goserelin-depot in the clinical management of uterine fibroids.
Cagnacci A; Paoletti AM; Soldani R; Angiolucci M; Arangino S; Falqui A; Melis GB
Clin Exp Obstet Gynecol; 1994; 21(4):263-5. PubMed ID: 7994879
[TBL] [Abstract][Full Text] [Related]
9. Clinical efficacy of goserelin (Zoladex) in the treatment of uterine myomas in infertile patients.
Kopitović V; Bujas M; Fistes Topalski N; Pjević M; Ilić D; Kapamadzija A; Bujas I
Med Pregl; 2001; 54(7-8):339-46. PubMed ID: 11905182
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of tibolone as "add-back therapy" in conjunction with a gonadotropin-releasing hormone analogue in the treatment of uterine fibroids.
Morris EP; Rymer J; Robinson J; Fogelman I
Fertil Steril; 2008 Feb; 89(2):421-8. PubMed ID: 17572410
[TBL] [Abstract][Full Text] [Related]
11. Use of goserelin depot, a gonadotropin-releasing hormone agonist, for the treatment of menorrhagia and severe anemia in women with leiomyomata uteri.
Candiani GB; Vercellini P; Fedele L; Arcaini L; Bianchi S; Candiani M
Acta Obstet Gynecol Scand; 1990; 69(5):413-5. PubMed ID: 2148663
[TBL] [Abstract][Full Text] [Related]
12. Urinary N-telopeptides to monitor bone resorption while on GnRH agonist therapy.
Marshall LA; Cain DF; Dmowski WP; Chesnut CH
Obstet Gynecol; 1996 Mar; 87(3):350-4. PubMed ID: 8598953
[TBL] [Abstract][Full Text] [Related]
13. Bone mineral density in premenopausal women treated for node-positive early breast cancer with 2 years of goserelin or 6 months of cyclophosphamide, methotrexate and 5-fluorouracil (CMF).
Fogelman I; Blake GM; Blamey R; Palmer M; Sauerbrei W; Schumacher M; Serin D; Stewart A; Wilpshaar W
Osteoporos Int; 2003 Dec; 14(12):1001-6. PubMed ID: 14530912
[TBL] [Abstract][Full Text] [Related]
14. Relationship between hormone receptor concentration and tumor shrinkage in uterine myoma after treatment with a GnRHa.
Wang PH; Lee WL; Chao HT; Shu LP; Kao HL; Wu CW; Yuan CC
Zhonghua Yi Xue Za Zhi (Taipei); 1999 May; 62(5):294-9. PubMed ID: 10389284
[TBL] [Abstract][Full Text] [Related]
15. Medroxyprogesterone acetate with Zoladex for long-term treatment of fibroids: effects on bone density and patient acceptability.
Caird LE; West CP; Lumsden MA; Hannan WJ; Gow SM
Hum Reprod; 1997 Mar; 12(3):436-40. PubMed ID: 9130735
[TBL] [Abstract][Full Text] [Related]
16. Uterine myoma after cessation of gonadotropin-releasing hormone agonist: ultrasound and histopathologic findings.
Wang PH; Yang AH; Yuan CC; Lee WL; Chao HT
Zhonghua Yi Xue Za Zhi (Taipei); 1998 Nov; 61(11):625-9. PubMed ID: 9872018
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of goserelin effectiveness based on assessment of inflammatory cytokines and symptoms in uterine leiomyoma.
Mohammed NH; Al-Taie A; Albasry Z
Int J Clin Pharm; 2020 Jun; 42(3):931-937. PubMed ID: 32350747
[TBL] [Abstract][Full Text] [Related]
18. Shrinkage of uterine fibroids during therapy with goserelin (Zoladex): a luteinizing hormone-releasing hormone agonist administered as a monthly subcutaneous depot.
West CP; Lumsden MA; Lawson S; Williamson J; Baird DT
Fertil Steril; 1987 Jul; 48(1):45-51. PubMed ID: 2954863
[TBL] [Abstract][Full Text] [Related]
19. A prospective, randomized trial of gonadotropin-releasing hormone agonist plus estrogen-progestin or progestin "add-back" regimens for women with leiomyomata uteri.
Friedman AJ; Daly M; Juneau-Norcross M; Rein MS; Fine C; Gleason R; Leboff M
J Clin Endocrinol Metab; 1993 Jun; 76(6):1439-45. PubMed ID: 8501148
[TBL] [Abstract][Full Text] [Related]
20. A randomized, placebo-controlled, dose-ranging trial comparing fulvestrant with goserelin in premenopausal patients with uterine fibroids awaiting hysterectomy.
Donnez J; Hervais Vivancos B; Kudela M; Audebert A; Jadoul P
Fertil Steril; 2003 Jun; 79(6):1380-9. PubMed ID: 12798886
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
